Navigation Links
ChemoCentryx Announces Pricing of Initial Public Offering
Date:2/8/2012

MOUNTAIN VIEW, Calif., Feb. 8, 2012 /PRNewswire/ -- ChemoCentryx, Inc. (NASDAQ: CCXI) announced today the pricing of its initial public offering of 4,500,000 shares of its common stock at $10.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by ChemoCentryx. In addition, the underwriters have a 30-day option to purchase up to an additional 675,000 shares of common stock from ChemoCentryx to cover over-allotments, if any.

Shares of ChemoCentryx's common stock will trade on the NASDAQ Global Select Market under the symbol "CCXI" beginning on February 8, 2012. The offering is expected to close on February 13, 2012, subject to customary closing conditions.

J.P. Morgan Securities LLC and Citigroup are acting as joint book-running managers of the offering, and Cowen and Company, LLC is acting as co-manager of the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 8, 2012. This offering is being made only by means of a prospectus, copies of which may be obtained from J. P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by phone at 866-803-9204, or from Citigroup, Attn: Prospectus Delivery Department, Brooklyn Army Terminal, 140 58th Street, Brooklyn, New York 11220 or by phone at 718-765-6732.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About ChemoCentryx 

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the c
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
2. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
3. ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes
4. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
5. ChemoCentryx to Present at the 29th Annual J.P. Morgan Healthcare Conference
6. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
7. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
8. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
9. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
10. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
11. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Fla. , Jan. 23, 2015  iMD Companies, Inc. (ICBU) ... to increase market share and grab a foothold in the ... influence, production capabilities and a presence in the sector, and ... facilitate the growth of hemp and medical marijuana, iMD is ...
(Date:1/23/2015)... plc (NYSE: MNK ) announced today that ... program. The open-ended authorization permits the company to repurchase ... "Funding additional initiatives and seeking attractive ... to pursue a range of focused growth strategies," said ...
(Date:1/22/2015)... Jan. 22, 2015  BiOptix is pleased to announce the ... President of Chemistry and Biochemistry. Scott joins the company after ... and Amgen throughout the course of his nearly 20 ... "Scott is a nationally recognized thought leader in the ...
Breaking Medicine Technology:iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... PARK, Calif.--(BUSINESS WIRE)--May,21, 2007 - ChemGenex Pharmaceuticals ... new clinical data relevant to the development,strategy ... the T315I mutation in Philadelphia-positive leukemias",by researchers ... of,Bologna, Italy (Haematologica Volume 92, pages 401-404) ...
... synergy, activity and patient tolerance observed in ... continuous,delivery therapy, WASHINGTON, May 21, 2007 /PRNewswire/ ... company, today announced,the presentation of final results ... of injectable omega interferon and ribavirin to,omega ...
Cached Medicine Technology:Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 2Independent Publication Confirms Growing Therapeutic Challenge of,T315I Mutation in Patients with CML, Notes ChemGenex 3Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference 2Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference 3Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference 4
(Date:1/22/2015)... January 22, 2015 Deer Path of Huntley ... a Valentine’s Day Happy Hour from 3 p.m. to 4 p.m. ... Regency Parkway in Huntley, Illinois, serves adults with physical disabilities between ... will include Valentine's Day treats, games and sweetheart-themed karaoke. , For ...
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort located in ... number one best large hotel for families in the United ... annual Travelers’ Choice Awards. , TripAdvisor represents the world’s ... to millions of unbiased and honest traveler reviews. The best ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
(Date:1/22/2015)... Dallas, TX (PRWEB) January 22, 2015 ... the issue of experience and person-centeredness in the long-term ... moving towards action across the continuum. The paper, “The ... the Continuum,” engages perspectives and practices of the patient, ...
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 Joan ... and keynote speaker at the upcoming 32nd Annual ... ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , shares ... would have gone undetected if she had not followed ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... characterization of renal transplant patients being weaned ... ... Data developed by Cylex in,conjunction with the University of Pittsburgh ... Canada, suggest,that cell-mediated immunity and anti-HLA antibody assays may be independent,measures ...
... COLUMBUS, Ohio Mothers play an important role in determining ... infants, according to new research. , A study of 97 ... care of their infants when they received active encouragement from ... important even after taking into account fathers and mothers views ...
... Three new studies published in the June 2008 ... on what role gender plays in the prognosis of ... the success rates of hearing aid implants in the ... wide variety of critical research being undertaken every day ...
... finds , , SATURDAY, May 31 (HealthDay News) -- ... survival in women with advanced breast cancer, new ... adding Avastin (bevacizumab) to the chemotherapy drug Taxol ... doubled progression-free survival. , Avastin is already approved ...
... Anti-angiogenesis drug prolonged progression-free survival, study finds , , ... drug Avastin to chemotherapy lengthened progression-free survival in ... , Previous studies have found that adding Avastin ... women with advanced breast cancer actually doubled progression-free ...
... Two Phase II studies demonstrated potential for pazopanib as a single,agent treatment ... -- In patients with stage I-III non-small cell lung cancer, ... monotherapy experienced a reduction in tumor volume ... an overall response rate of 35 percent. ...
Cached Medicine News:Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 2Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 3Health News:Mom's behavior key to dad's involvement in child care 2Health News:Mom's behavior key to dad's involvement in child care 3Health News:New research offers insight into oral cancer, chronic pediatric ear infections, and hearing health 2Health News:Avastin Added to Chemo Helps Women With Advanced Breast Cancer 2Health News:Avastin Added to Chemo Helps Women With Advanced Breast Cancer 3Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 2Health News:Avastin Added to Chemo Helps Women With Advanced Cancer 3Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 2Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 3Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 4Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 5Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 6Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 7Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 8
... IEC60601-2-51 new international standard for digital ... performance. ECG data can be reviewed ... with the optional ECG Viewer software. ... in other countries, and it truly ...
... The Stat Profile pHOx series consists of six ... and critical care profiles. Measured tests include pH, ... %, hematocrit, hemoglobin, sodium, potassium, ionized calcium, chloride, ... less than one minute. Its space saving design ...
... 25 years, Bio-logic has demonstrated continuous innovations ... introduced the first Digital EEG system brings ... you! Ceegraph VISION is the first Windows ... to integrate all your EEG needs: epilepsy ...
Optoelectronic stimulator, "ganzfeld" stimulations for flash VEP, flash ERG and sensory EOG. Pattern stimulations for ERG and VEP, multifocal stimulations for ERG and VEP, complies with international...
Medicine Products: